NPF Joins Coalition Letter Asking HHS to Reconsider Cost Sharing Provision in 2021 Notice of Benefit & Payment Parameters

05/05/2020

The COVID-19 pandemic is necessitating extraordinary efforts by all Americans to reduce the spread of the virus and minimize the loss of life. As we continue through this first wave of the pandemic, we are already witnessing the broad effects this crisis is having not only on the health of individuals and families, but also on their economic well-being. In light of these concerns, we urge HHS to reconsider the proposed provision in the 2021 Notice of Benefit Payment Parameters that grants issuers the discretion not to count drug copayment assistance towards a member’s annual cost sharing, regardless of whether a generic exists.

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorMy Psoriasis Team logo

Copyright © 1996-2020 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.